stocksfeed.ai
← Back to news feed

MRK overview

MRK
Merck & Company, Inc.
137.78
USD
-10.14 (-6.86%)since Nov 16, 2026

News about MRK

5 stories shown

MRKproduct launch

Merck & Co. has discontinued its clinical development program for the investigational drug nemtabrutinib following a safety review.

Benzinga
View original
MRKdividend

Merck has announced a 3.5% increase in its quarterly dividend to $0.88 per share.

Seeking Alpha
View original
LLYMRKanalyst commentary

Analysts identify Eli Lilly, Roche, and Merck as attractive Big Pharma stocks, driven by raised guidance and long-term recovery prospects.

Seeking Alpha
View original
MRKRVMDregulation

The FDA has reportedly halted its controversial fast-track drug review pilot program amid internal turmoil and a prolonged leadership vacuum.

Benzinga
View original
MRNAMRKproduct launch

Major pharmaceutical companies are investing billions in vaccines, including promising cancer and shingles vaccines, despite political hurdles.

MarketWatch
View original